What is Genemod?
Genemod provides cloud-based inventory and product management solutions tailored for biotech companies, aiming to enhance productivity and accelerate the development of next-generation therapies. Life scientists and researchers leverage Genemod's platform for collaborative research, efficient reagent inventory management, and streamlined workflow optimization. The company's vision is to empower organizations, including leading biotech institutions like the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, to expedite the discovery of cures by offering sophisticated pre-clinical software tools.
How much funding has Genemod raised?
Genemod has raised a total of $7.7M across 3 funding rounds:
Other Financing Round
$1.5M
Angel/Seed
$1.7M
Angel/Seed
$4.5M
Other Financing Round (2020): $1.5M, investors not publicly disclosed
Angel/Seed (2020): $1.7M led by Canaan Partners, Omicron, Defy.vc, Unpopular Ventures, and Underdog Labs
Angel/Seed (2023): $4.5M supported by LDV Partners, Vulcan Medical Ventures, Defy, and Dolby Family Ventures
Key Investors in Genemod
Canaan Partners
Canaan Partners is an early-stage venture capital firm specializing in technology and healthcare, supporting companies from seed to growth stages in areas like enterprise software and biopharma.
LDV Partners
LDV Partners is dedicated to transforming innovative ideas into successful companies by collaborating closely with visionary founders, providing strategic insights and resources to foster growth in disruptive technologies.
Defy
Defy VC is an early-stage venture capital firm dedicated to supporting authentic founders in building enduring companies, focusing on exceptional entrepreneurs who aim to defy expectations and change the status quo.
What's next for Genemod?
With the recent major strategic investment, Genemod is poised to further enhance its technological offerings and expand its market reach. This capital infusion is expected to fuel innovation in its cloud-based solutions, enabling more biotech firms to collaborate effectively and manage their research pipelines with greater efficiency. The company's focus on driving faster therapeutic development suggests a strategic direction towards deepening its integration with research institutions and potentially exploring new software functionalities that address emerging challenges in pre-clinical research and drug discovery. The sustained investor interest indicates a strong belief in Genemod's potential to become a pivotal player in the life sciences technology landscape.
See full Genemod company page
